1. Catalog
  2. Nodes
  3. path(MESH:Depression)

path(MESH:Depression)

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
Depression
Namespace
mesh
Namespace Version
20181007
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns

Appears in Networks 8

Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. v1.0.0

This file encodes the article Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia by Choi et al, 2014

Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System v1.0.0

Alzheimer's Disease: Targeting the Cholinergic System v1.0.0

Neural Systems Governed by Nicotinic Acetylcholine Receptors: Emerging Hypotheses v1.0.0

Nicotinic Receptor Abnormalities of Alzheimer’s Disease: Therapeutic Implications v1.0.0

Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system v1.0.0

This document contains the curation of the review article Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system by Taly et al. 2009

Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors. v1.0.0

Discriminative Stimulus Properties of S(−)-Nicotine: “A Drug for All Seasons v1.0.0

In-Edges 10

p(FPLX:CHRN) association path(MESH:Depression) View Subject | View Object

Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression. PubMed:17009926

Appears in Networks:

path(MESH:"Alzheimer Disease") increases path(MESH:Depression) View Subject | View Object

AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis PubMed:24511233

Appears in Networks:

a(MESH:"Cholinergic Neurons") decreases path(MESH:Depression) View Subject | View Object

It has been postulated that the loss of cholinergic neurons and the consequent impairment in dopaminergic transmission could be the main factors underling AD-related psychiatric symptoms PubMed:26813123

Appears in Networks:
Annotations
MeSH
CA3 Region, Hippocampal
MeSH
Alzheimer Disease

path(MESH:"Alzheimer Disease") positiveCorrelation path(MESH:Depression) View Subject | View Object

In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression PubMed:26813123

Appears in Networks:
Annotations
MeSH
CA3 Region, Hippocampal

bp(GO:"synaptic transmission, cholinergic") association path(MESH:Depression) View Subject | View Object

In 2011, we know that cholinergic actions in the brain govern various processes: cognition (attention and executive function) (Couey et al., 2007; Levin and Rezvani, 2007; Heath and Picciotto, 2009; Howe et al., 2010), learning and memory (Gould, 2006; Couey et al., 2007; Levin and Rezvani, 2007), mood (anxiety, depression) (Picciotto et al., 2008), reward (addiction, craving) (Tang and Dani, 2009), and sensory processing (Heath and Picciotto, 2009) PubMed:21482353

Appears in Networks:
Annotations
MeSH
Brain

p(FPLX:CHRN) association path(MESH:Depression) View Subject | View Object

The nAChRs are found to be involved in a complex range of central nervous system disorders including Alzheimer’s disease (AD), Parkinson’s disease, schizophrenia, Tourette’s syndrome, anxiety, depression, and epilepsy (Newhouse and Kelton 2000; Newhouse et al 1997; Paterson and Nordberg 2000) PubMed:11230871

Appears in Networks:

p(MESH:"Receptors, Nicotinic") association path(MESH:Depression) View Subject | View Object

nAChRs contribute to cognitive function, and changes in their number and/or func- tion are associated with various pathological conditions such as cognitive disorders, anxiety, depression, Alzheimer’s and Parkinson’s disease, pain and epilepsy PubMed:28901280

Appears in Networks:

a(CHEBI:Mecamylamine) increases path(MESH:Depression) View Subject | View Object

In addition, mecamylamine can produce CNS effects that include tremor, mental confusion, seizures, mania, and depression but the mechanisms by which these effects are produced are unclear PubMed:28391535

Appears in Networks:

a(CHEBI:bupropion) decreases path(MESH:Depression) View Subject | View Object

It is prescribed as medication for the treatment of depression (Wellbutrin®) and/or as an adjunct in smoking cessation therapy (Zyban®). PubMed:28391535

Appears in Networks:

path(MESH:"Smoking Cessation") increases path(MESH:Depression) View Subject | View Object

(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite. PubMed:28391535

Appears in Networks:

Out-Edges 6

path(MESH:Depression) association p(FPLX:CHRN) View Subject | View Object

Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression. PubMed:17009926

Appears in Networks:

path(MESH:Depression) positiveCorrelation path(MESH:"Alzheimer Disease") View Subject | View Object

In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression PubMed:26813123

Appears in Networks:
Annotations
MeSH
CA3 Region, Hippocampal

path(MESH:Depression) association bp(GO:"synaptic transmission, cholinergic") View Subject | View Object

In 2011, we know that cholinergic actions in the brain govern various processes: cognition (attention and executive function) (Couey et al., 2007; Levin and Rezvani, 2007; Heath and Picciotto, 2009; Howe et al., 2010), learning and memory (Gould, 2006; Couey et al., 2007; Levin and Rezvani, 2007), mood (anxiety, depression) (Picciotto et al., 2008), reward (addiction, craving) (Tang and Dani, 2009), and sensory processing (Heath and Picciotto, 2009) PubMed:21482353

Appears in Networks:
Annotations
MeSH
Brain

path(MESH:Depression) association p(FPLX:CHRN) View Subject | View Object

The nAChRs are found to be involved in a complex range of central nervous system disorders including Alzheimer’s disease (AD), Parkinson’s disease, schizophrenia, Tourette’s syndrome, anxiety, depression, and epilepsy (Newhouse and Kelton 2000; Newhouse et al 1997; Paterson and Nordberg 2000) PubMed:11230871

Appears in Networks:

path(MESH:Depression) increases a(CHEBI:choline) View Subject | View Object

using in vivo proton NMR imaging, levels of choline (the rate-limiting precursor to endogeneous ACh) were shown to be increased in the brains of patients with depression217 and in the prefrontal cortex of adolescents with depression218 compared with the control group. PubMed:19721446

Appears in Networks:
Annotations
MeSH
Brain
MeSH
Prefrontal Cortex
Text Location
Review

path(MESH:Depression) association p(MESH:"Receptors, Nicotinic") View Subject | View Object

nAChRs contribute to cognitive function, and changes in their number and/or func- tion are associated with various pathological conditions such as cognitive disorders, anxiety, depression, Alzheimer’s and Parkinson’s disease, pain and epilepsy PubMed:28901280

Appears in Networks:

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.